Abstract: The research findings published by National Surgical Adjuvant Breast and Bowel Project have continued to change the clinical practice of earlystage breast cancer over the past decade. Sentinel lymph node biopsy has become the new surgical operation standard. The aromatase inhibitor adjuvant endocrine therapy cycle has been extended from 5 years to 10 years, which benefits the patients with high risk and reactivity. Chemotherapy combined with trastuzumab has become the standard adjuvant therapy strategy of human epidermal growth factor receptor 2 positive invasive breast cancer. In addition, the research progress is also related to the optimization of the fields including the postoperative adjuvant chemotherapy and neoadjuvant chemotherapy.

Key words: Breast neoplasms, Surgical procedures, Adjuvant therapy